New drug targets Hard-to-Treat cancers with specific gene change
NCT ID NCT06287918
First seen Jan 27, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This early study tests a new drug called 3HP-2827 in adults with advanced solid tumors that have a specific genetic change (FGFR2 alteration). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 130 participants will take part in two stages: first to find the right dose, then to see how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS WITH FGFR2 ALTERATIONS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.